Breaking News Instant updates and real-time market news.

PFE

Pfizer

$45.64

0.13 (0.29%)

, ABBV

AbbVie

$90.04

0.12 (0.13%)

10:02
11/30/18
11/30
10:02
11/30/18
10:02

Pfizer signs licensing agreements with AbbVie resolving IP matters

Pfizer (PFE) announced that it has signed licensing agreements with AbbVie (ABBV), resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. Pfizer may launch its adalimumab biosimilar upon approval by the European Medicines Agency in Europe. In the United States, the license period will begin on November 20, 2023. All litigation pending between the parties will be withdrawn. The financial details of the agreements are confidential.

PFE

Pfizer

$45.64

0.13 (0.29%)

ABBV

AbbVie

$90.04

0.12 (0.13%)

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

  • 18

    Dec

PFE Pfizer
$45.64

0.13 (0.29%)

11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/07/18
CHDN
11/07/18
NO CHANGE
Target $70
CHDN
Buy
uniQure price target raised to $70 from $50 at Chardan
Chardan analyst Gbola Amusa increased his price target on uniQure (QURE) to $70 from $50, stating that he believes the market is missing important dynamics in uniQure's favor over hemB competition from Pfizer (PFE) and Spark Therapeutics (ONCE). Amusa said uniQure's manufacturing is "much more scalable" than Pfizer's and he also believes uniQure's IP may cover the construct utilized by Pfizer. Amusa keeps a Buy rating on uniQure shares.
ABBV AbbVie
$90.04

0.12 (0.13%)

11/23/18
RHCO
11/23/18
NO CHANGE
Target $135
RHCO
Buy
AbbVie gets 'another leg of growth' on FDA approval of Venclexta, says SunTrust
SunTrust analyst John Boris kept his Buy rating and $135 price target on AbbVie (ABBV), saying the latest FDA approval for its Venclexta for the treatment of newly-diagnosed acute myeloid leukemia in adults aged 75 years or more that is jointly marketed with Roche (RHHBY) gives the company "another leg of growth" with over $1B in estimated peak sales. The analyst sees the results from a phase-3 Bellini study evaluating the combination of Venclexta, Velcade, and dexamethasone in relapsed and refractory Multiple Myeloma expected in the first half of 2019 as the next potential catalyst for the program.
11/06/18
ARGS
11/06/18
NO CHANGE
Target $115
ARGS
Buy
AbbVie price target lowered to $115 from $130 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $115 to reflect the competitive environment for its Humira sales from biosimilars in Europe, but also kept his Buy rating and raised his FY18 EPS view by 9c to $7.91 and FY19 by 12c to $9.00. The analyst says Humira should continue to post "solid growth" in the U.S. markets, and also cites the prospects of its Imbruvica, Venclexta Orilissa and hepatitis C drugs along with its remaining product pipeline. Toung contends that the "incremental sales of new faster-growing products can more than offset the expected decline in overseas sales of Humira".
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
AbbVie Q3 results do not convince Piper Jaffray to get off sidelines
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars.
10/30/18
NOMU
10/30/18
NO CHANGE
Target $140
NOMU
Buy
Galapagos price target raised to $140 from $124 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Galapagos NV to $140 following last week's Q3 results and the sale of its partnered-cystic fibrosis program back to AbbVie (ABBV) for $45M upfront and $200M in milestones. The analyst views the upfront payments as upside to expectations and keeps a Buy rating on Galapagos shares.

TODAY'S FREE FLY STORIES

MO

Altria Group

$48.31

-0.03 (-0.06%)

10:14
11/19/19
11/19
10:14
11/19/19
10:14
Hot Stocks
NY AG announces 'comprehensive' lawsuit against Juul Labs for youth vaping sales »

New York Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

SHAK

Shake Shack

$60.50

-1.25 (-2.02%)

, LHX

L3Harris Technologies

$203.50

0.74 (0.36%)

10:13
11/19/19
11/19
10:13
11/19/19
10:13
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

SHAK

Shake Shack

$60.50

-1.25 (-2.02%)

LHX

L3Harris Technologies

$203.50

0.74 (0.36%)

PHAT

Phathom Pharmaceuticals

$23.00

-1.88 (-7.56%)

CABA

Cabaletta Bio

$14.79

0.95 (6.86%)

AGEN

Agenus

$4.30

-0.08 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.64

-0.97 (-2.45%)

, HP

Helmerich & Payne

$37.54

-1.3 (-3.35%)

10:13
11/19/19
11/19
10:13
11/19/19
10:13
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

T

AT&T

$38.64

-0.97 (-2.45%)

HP

Helmerich & Payne

$37.54

-1.3 (-3.35%)

PSA

Public Storage

$211.30

-2.16 (-1.01%)

LEG

Leggett & Platt

$53.09

-0.45 (-0.84%)

ITUB

Itau Unibanco

$8.27

-0.14 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

AVGO

Broadcom

$322.53

11.58 (3.72%)

, MXL

MaxLinear

$20.14

0.3 (1.51%)

10:13
11/19/19
11/19
10:13
11/19/19
10:13
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

AVGO

Broadcom

$322.53

11.58 (3.72%)

MXL

MaxLinear

$20.14

0.3 (1.51%)

BOLD

Audentes Therapeutics

$27.32

1.77 (6.93%)

OKTA

Okta

$124.81

3.6 (2.97%)

AVB

AvalonBay

$216.24

1.01 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

  • 16

    Dec

AXAS

Abraxas Petroleum

$0.28

(0.00%)

10:11
11/19/19
11/19
10:11
11/19/19
10:11
Downgrade
Abraxas Petroleum rating change  »

Abraxas Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
11/19/19
11/19
10:10
11/19/19
10:10
General news
Quarterly Services Report [Advance] Iformation Revenue data reported »

Quarterly Services Report…

10:10
11/19/19
11/19
10:10
11/19/19
10:10
General news
Quarterly Services Report [Advance] Iformation Revenue data reported »

Quarterly Services Report…

BRY

Berry Petroleum

$10.90

-0.405 (-3.58%)

10:10
11/19/19
11/19
10:10
11/19/19
10:10
Downgrade
Berry Petroleum rating change  »

Berry Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
11/19/19
11/19
10:10
11/19/19
10:10
General news
E-Commerce Retail Sales E- Q/Q Change SAAR data reported »

E-Commerce Retail Sales…

CHK

Chesapeake

$0.59

-0.0496 (-7.70%)

10:10
11/19/19
11/19
10:10
11/19/19
10:10
Downgrade
Chesapeake rating change  »

Chesapeake downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPE

Callon Petroleum

$3.83

-0.115 (-2.92%)

10:10
11/19/19
11/19
10:10
11/19/19
10:10
Downgrade
Callon Petroleum rating change  »

Callon Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$70.11

-1.15 (-1.61%)

10:10
11/19/19
11/19
10:10
11/19/19
10:10
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares China Large-Cap ETF

$41.74

0.455 (1.10%)

10:10
11/19/19
11/19
10:10
11/19/19
10:10
Options
$1.5M Call buyer in China ETF »

$1.5M Call buyer in China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$74.48

-1.24 (-1.64%)

10:09
11/19/19
11/19
10:09
11/19/19
10:09
Downgrade
Diamondback Energy rating change  »

Diamondback Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGY

Magnolia Oil & Gas

$11.32

-0.15 (-1.31%)

10:09
11/19/19
11/19
10:09
11/19/19
10:09
Downgrade
Magnolia Oil & Gas rating change  »

Magnolia Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.49

-0.135 (-5.14%)

10:09
11/19/19
11/19
10:09
11/19/19
10:09
Downgrade
Oasis Petroleum rating change  »

Oasis Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWN

Southwestern Energy

$1.96

-0.015 (-0.76%)

10:08
11/19/19
11/19
10:08
11/19/19
10:08
Downgrade
Southwestern Energy rating change  »

Southwestern Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$322.68

11.73 (3.77%)

, T

AT&T

$38.65

-0.96 (-2.42%)

10:08
11/19/19
11/19
10:08
11/19/19
10:08
On The Fly
AT&T, MSG Networks downgrades among today's top analyst calls »

Check out today's top…

AVGO

Broadcom

$322.68

11.73 (3.77%)

T

AT&T

$38.65

-0.96 (-2.42%)

I

Intelsat

$5.90

-2.08 (-26.07%)

MSGN

MSG Networks

$17.82

-0.675 (-3.65%)

IMAX

Imax

$21.28

0.4 (1.92%)

AMC

AMC Entertainment

$8.79

0.3 (3.53%)

CNK

Cinemark

$34.42

0.295 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 02

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 17

    Dec

  • 29

    Jan

WHLR

Wheeler REIT

$1.85

(0.00%)

10:08
11/19/19
11/19
10:08
11/19/19
10:08
Hot Stocks
Stilwell Group urges Wheeler REIT shareholders to vote for director nominees »

The Stilwell Group, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

CHWY

Chewy

$22.50

0.395 (1.79%)

10:05
11/19/19
11/19
10:05
11/19/19
10:05
Options
Chewy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

TGT

Target

$110.21

-0.38 (-0.34%)

, AMZN

Amazon.com

$1,756.23

3.53 (0.20%)

10:04
11/19/19
11/19
10:04
11/19/19
10:04
Earnings
Fly Intel: What to watch in Target's earnings report »

Target (TGT) is scheduled…

TGT

Target

$110.21

-0.38 (-0.34%)

AMZN

Amazon.com

$1,756.23

3.53 (0.20%)

WMT

Walmart

$120.20

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

FBIO

Fortress Biotech

$1.85

-0.04 (-2.12%)

10:04
11/19/19
11/19
10:04
11/19/19
10:04
Conference/Events
Fortress Biotech management to meet with Philadelphia Securities Association »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MMS

Maximus

$75.60

-1.93 (-2.49%)

10:01
11/19/19
11/19
10:01
11/19/19
10:01
Earnings
Maximus says fiscal 2020 revenue will be stronger in first half »

Maximus said in earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PFG

Principal Financial

$54.77

0.5 (0.92%)

10:01
11/19/19
11/19
10:01
11/19/19
10:01
Conference/Events
Principal Financial management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 11

    Dec

VAL

Valaris

$3.82

-0.38 (-9.05%)

10:00
11/19/19
11/19
10:00
11/19/19
10:00
Hot Stocks
Valaris falls -8.8% »

Valaris is down -8.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.